Eiger Biopharmaceuticals Probability of Future Stock Price Finishing Over 0.74
| EIGRDelisted Stock | USD 0.74 0.03 3.90% |
Eiger |
Eiger Biopharmaceutica Target Price Odds to finish over 0.74
The tendency of Eiger Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 0.74 | 90 days | 0.74 | about 90.88 |
Based on a normal probability distribution, the odds of Eiger Biopharmaceutica to move above the current price in 90 days from now is about 90.88 (This Eiger Biopharmaceuticals probability density function shows the probability of Eiger Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days Eiger Biopharmaceutica has a beta of 0.57 suggesting as returns on the market go up, Eiger Biopharmaceutica average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Eiger Biopharmaceuticals will be expected to be much smaller as well. Additionally Eiger Biopharmaceuticals has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Eiger Biopharmaceutica Price Density |
| Price |
Predictive Modules for Eiger Biopharmaceutica
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Eiger Biopharmaceuticals. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Eiger Biopharmaceutica Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Eiger Biopharmaceutica is not an exception. The market had few large corrections towards the Eiger Biopharmaceutica's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Eiger Biopharmaceuticals, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Eiger Biopharmaceutica within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.49 | |
β | Beta against Dow Jones | 0.57 | |
σ | Overall volatility | 0.18 | |
Ir | Information ratio | -0.08 |
Eiger Biopharmaceutica Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Eiger Biopharmaceutica for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Eiger Biopharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Eiger Biopharmaceutica is not yet fully synchronised with the market data | |
| Eiger Biopharmaceutica has some characteristics of a very speculative penny stock | |
| Eiger Biopharmaceutica has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 15.77 M. Net Loss for the year was (74.96 M) with profit before overhead, payroll, taxes, and interest of 11.65 M. | |
| Eiger Biopharmaceuticals currently holds about 141.79 M in cash with (74.55 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.22, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
Eiger Biopharmaceutica Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Eiger Stock often depends not only on the future outlook of the current and potential Eiger Biopharmaceutica's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Eiger Biopharmaceutica's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 1.5 M | |
| Cash And Short Term Investments | 25.4 M |
Eiger Biopharmaceutica Technical Analysis
Eiger Biopharmaceutica's future price can be derived by breaking down and analyzing its technical indicators over time. Eiger Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Eiger Biopharmaceuticals. In general, you should focus on analyzing Eiger Stock price patterns and their correlations with different microeconomic environments and drivers.
Eiger Biopharmaceutica Predictive Forecast Models
Eiger Biopharmaceutica's time-series forecasting models is one of many Eiger Biopharmaceutica's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Eiger Biopharmaceutica's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Eiger Biopharmaceuticals
Checking the ongoing alerts about Eiger Biopharmaceutica for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Eiger Biopharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Eiger Biopharmaceutica is not yet fully synchronised with the market data | |
| Eiger Biopharmaceutica has some characteristics of a very speculative penny stock | |
| Eiger Biopharmaceutica has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 15.77 M. Net Loss for the year was (74.96 M) with profit before overhead, payroll, taxes, and interest of 11.65 M. | |
| Eiger Biopharmaceuticals currently holds about 141.79 M in cash with (74.55 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.22, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in Eiger Stock
If you are still planning to invest in Eiger Biopharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Eiger Biopharmaceutica's history and understand the potential risks before investing.
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Money Managers Screen money managers from public funds and ETFs managed around the world |